
1. high throughput. 2017 oct 30;6(4). pii: e15. doi: 10.3390/ht6040015.

study humoral immune response towards hcv genotype 4 using bead-based
multiplex serological assay.

filomena a(1), göpfert jc(2), duffy d(3)(4)(5), pol s(6)(7)(8)(9), abdel-hamid
m(10), esmat g(11), fontanet a(12)(13), albert ml(14)(15)(16), joos to(17),
schneiderhan-marra n(18).

author information: 
(1)nmi natural medical sciences institute university tuebingen,
72770 reutlingen, germany. angela.filomena@gmx.de.
(2)nmi natural medical sciences institute university tuebingen,
72770 reutlingen, germany. jens.goepfert@nmi.de.
(3)immunobiology dendritic cells, institute pasteur, 75015 paris, france.
darragh.duffy@pasteur.fr.
(4)inserm u1223, institute pasteur, 75015 paris, france.
darragh.duffy@pasteur.fr.
(5)centre translational research, institute pasteur, 75015 paris, france.
darragh.duffy@pasteur.fr.
(6)immunobiology dendritic cells, institute pasteur, 75015 paris, france.
stanislas.pol@pasteur.fr.
(7)inserm u1223, institute pasteur, 75015 paris, france.
stanislas.pol@pasteur.fr.
(8)centre translational research, institute pasteur, 75015 paris, france.
stanislas.pol@pasteur.fr.
(9)unité d'hépatologie, groupe hospitalier cochin hôtel-dieu, université rené
descartes, 75006 paris, france. stanislas.pol@pasteur.fr.
(10)department microbiology, faculty medicine, minia university, minia
11432, egypt. vhrl@link.net.
(11)endemic medicine hepatogastroenterology, faculty medicine, cairo
university, cairo 12613, egypt. gesmat@gamalesmat.com.
(12)emerging disease epidemiology unit, institute pasteur, 75015 paris, france.
arnaud.fontanet@pasteur.fr.
(13)conservatoire national des arts et métiers, unité pacri, 75003 paris, france.
arnaud.fontanet@pasteur.fr.
(14)immunobiology dendritic cells, institute pasteur, 75015 paris, france.
matthew.albert@pasteur.fr.
(15)inserm u1223, institute pasteur, 75015 paris, france.
matthew.albert@pasteur.fr.
(16)centre translational research, institute pasteur, 75015 paris, france.
matthew.albert@pasteur.fr.
(17)nmi natural medical sciences institute university tuebingen,
72770 reutlingen, germany. thomas.joos@nmi.de.
(18)nmi natural medical sciences institute university tuebingen,
72770 reutlingen, germany. nicole.schneiderhan@nmi.de.

hepatitis c one leading causes hepatocellular carcinoma remains 
at high prevalence egypt resource-limited countries. several
hepatitis c virus (hcv) genotypes distributed throughout world, with
genotype 4 common north central africa. developed a
multiplex serological assay detection hcv specific humoral immune 
response, focus genotype 4. multiplex hcv assay used twelve 
antigenic regions different hcv proteins (core, non-structural (ns)
proteins ns3, ns4, ns5a, ns5b) validated assay technically and
clinically. comparison commercially available test, assay revealed 
higher sensitivity genotype 4, therefore suited studying
immune seroconversion samples acutely infected egyptian hcv patients.
furthermore, assay discriminates acutely chronically infected hcv
patients. 296 well characterized hcv patient samples, 83.9% acute
samples 86.5% chronic samples could correctly classified. sum,
this newly developed serological hcv assay higher sensitivity hcv
genotype 4, thus improve diagnostic accuracy. discrimination 
of acutely chronically infected hcv patients assay may useful in
supporting clinical management hcv patients.

doi: 10.3390/ht6040015 
pmcid: pmc5748594
pmid: 29855459 

conflict interest statement: a.f., j.c.g., d.d., m.a.h., g.e., m.l.a., a.f.,
t.o.j., n.s.m. conflict interest. s.p. speaker bristol-myers
squibb (bms), boehringer ingelheim, janssen, gilead, merck sharp & dohme (msd),
abbvie; received grants bms, gilead, msd board member bms,
boehringer ingelheim, janssen, gilead, msd, abbvie.

